Prostate cancer is one of the most common types of cancer in men and its treatment was constricted to surgery for confined state and androgen ablation for advanced disease until new options have become available. The present book covers a broad range of novel aspects of prostate cancer diagnosis, treatment and patient care, as well as new research on relevant cell biology.
Endocrine disruptors function by: (i) Mimicking the action of a
naturally-produced hormone, such as estrogen or testosterone,
thereby setting off similar chemical reactions in the body; (ii)
Blocking hormone receptors in cells, thereby preventing the action
of normal hormones; or (iii) Affecting the synthesis, transport,
metabolism and excretion of hormones, thus altering the
concentrations of natural hormones.
Diagnosis and Treatment by Clinical State
The disease continuum—from the appearance of a preneoplastic and invasive lesion localized to the prostate, to a metastatic lesion that results in symptoms and, ultimately, mortality from prostate cancer—can span decades. Management at all points is centered on competing risks that are defined by considering the disease as a series of clinical states (Fig. 91-1).